# Oxcarbazepine‐induced Stevens‐Johnson Syndrome: A Case Report

## Metadata
**Authors:** Lung‐Chang Lin, Ping‐Chin Lai, Sheau‐Fang Yang, Rei‐Cheng Yang
**Journal:** The Kaohsiung Journal of Medical Sciences
**Date:** 2009 May 18
**DOI:** [10.1016/S1607-551X(09)70045-2](https://doi.org/10.1016/S1607-551X(09)70045-2)
**PMID:** 19321411
**PMCID:** PMC11917620
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11917620/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC11917620/pdf/KJM2-25-82.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC11917620/pdf/KJM2-25-82.pdf)

## Abstract

Although carbamazepine (CBZ) is the most common cause of Stevens‐Johnson syndrome (SJS), a new anticonvulsant, oxcarbazepine, which is structurally related to carbamazepine, has been shown to induce SJS, although extremely rarely. Recently, a strong association was found between human leukocyte antigen (HLA) B*1502 and CBZ‐induced SJS/TEN in a Han Chinese population. Here, we report a case with SJS, which was induced by oxcarbazepine. HLA genotyping in the patient showed HLA‐B*1518/B*4001. HLA‐B*1518 is a HLA‐B15 variant. The genetic significance of HLA‐B*1518 in association with oxcarbazepine‐induced SJS needs to be further studied.

Keywords: oxcarbazepine, Stevens‐Johnson syndrome

## Full Text

The Full Text of this article is available as a [PDF](/articles/instance/11917620/pdf/KJM2-25-82.pdf) (881.6 KB).

## References

1. Auquier‐Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens‐Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002; 138: 1019–1024.  [DOI](https://doi.org/10.1001/archderm.138.8.1019) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/12164739/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Arch%20Dermatol&title=Correlations%20between%20clinical%20patterns%20and%20causes%20of%20erythema%20multiforme%20majus,%20Stevens%E2%80%90Johnson%20syndrome,%20and%20toxic%20epidermal%20necrolysis:%20results%20of%20an%20international%20prospective%20study&author=A%20Auquier%E2%80%90Dunant&author=M%20Mockenhaupt&author=L%20Naldi&volume=138&publication_year=2002&pages=1019-1024&pmid=12164739&doi=10.1001/archderm.138.8.1019&)

2. Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of Stevens‐Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology. 2005; 64: 1134–1138.  [DOI](https://doi.org/10.1212/01.WNL.0000156354.20227.F0) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/15824335/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurology&title=Risk%20of%20Stevens%E2%80%90Johnson%20syndrome%20and%20toxic%20epidermal%20necrolysis%20in%20new%20users%20of%20antiepileptics&author=M%20Mockenhaupt&author=J%20Messenheimer&author=P%20Tennis&volume=64&publication_year=2005&pages=1134-1138&pmid=15824335&doi=10.1212/01.WNL.0000156354.20227.F0&)

3. Medical Economics . Physician's desk reference. 55th edition. Montvale, NJ: Thomson PDR. 2001.  [Google Scholar](https://scholar.google.com/scholar_lookup?title=Physician's%20desk%20reference&publication_year=2001&)

4. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens‐Johnson syndrome. Nature. 2004; 428: 486.  [DOI](https://doi.org/10.1038/428486a) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/15057820/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nature&title=Medical%20genetics:%20a%20marker%20for%20Stevens%E2%80%90Johnson%20syndrome&author=WH%20Chung&author=SI%20Hung&author=HS%20Hong&volume=428&publication_year=2004&pages=486&pmid=15057820&doi=10.1038/428486a&)

5. Frisch PO, Ruiz‐Maldonado R. Erythema multiforme, Stevens‐Johnson syndrome and toxic epidermal necrosis. In Freedberg IM, Eisen AZ, Wolff K, et al., eds. Fitzpatrick's Dermatology in General Medicine. 6th edition. New York: McGraw‐Hill. 2003, 543–557.  [Google Scholar](https://scholar.google.com/scholar_lookup?title=Fitzpatrick's%20Dermatology%20in%20General%20Medicine&author=PO%20Frisch&author=R%20Ruiz%E2%80%90Maldonado&publication_year=2003&)

6. Pirmohamed M, Lin K, Chadwick D, et al. TNFα promoter region gene polymorphism in carbamazepinehypersensitive patients. Neurology. 2001; 56: 890–896.  [DOI](https://doi.org/10.1212/wnl.56.7.890) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/11294926/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurology&title=TNF%CE%B1%20promoter%20region%20gene%20polymorphism%20in%20carbamazepinehypersensitive%20patients&author=M%20Pirmohamed&author=K%20Lin&author=D%20Chadwick&volume=56&publication_year=2001&pages=890-896&pmid=11294926&doi=10.1212/wnl.56.7.890&)

7. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens‐Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008; 58: 25–32.  [DOI](https://doi.org/10.1016/j.jaad.2007.08.036) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17919772/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Am%20Acad%20Dermatol&title=Allopurinol%20is%20the%20most%20common%20cause%20of%20Stevens%E2%80%90Johnson%20syndrome%20and%20toxic%20epidermal%20necrolysis%20in%20Europe%20and%20Israel&author=S%20Halevy&author=PD%20Ghislain&author=M%20Mockenhaupt&volume=58&publication_year=2008&pages=25-32&pmid=17919772&doi=10.1016/j.jaad.2007.08.036&)

8. Devi K, George S, Criton S, et al. Carbamazepine— the commonest cause of toxic epidermal necrolysis and Stevens‐Johnson syndrome: a study of 7 years. India J Dermatol Venereol Leprol. 2005; 71: 325–328.  [DOI](https://doi.org/10.4103/0378-6323.16782) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/16394456/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=India%20J%20Dermatol%20Venereol%20Leprol&title=Carbamazepine%E2%80%94%20the%20commonest%20cause%20of%20toxic%20epidermal%20necrolysis%20and%20Stevens%E2%80%90Johnson%20syndrome:%20a%20study%20of%207%20years&author=K%20Devi&author=S%20George&author=S%20Criton&volume=71&publication_year=2005&pages=325-328&pmid=16394456&doi=10.4103/0378-6323.16782&)

9. Dogan EA, Usta BE, Bilgen R, et al. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav. 2008; 13: 156–161.  [DOI](https://doi.org/10.1016/j.yebeh.2008.02.001) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18331816/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Epilepsy%20Behav&title=Efficacy,%20tolerability,%20and%20side%20effects%20of%20oxcarbazepine%20monotherapy:%20a%20prospective%20study%20in%20adult%20and%20elderly%20patients%20with%20newly%20diagnosed%20partial%20epilepsy&author=EA%20Dogan&author=BE%20Usta&author=R%20Bilgen&volume=13&publication_year=2008&pages=156-161&pmid=18331816&doi=10.1016/j.yebeh.2008.02.001&)

10. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?. Epilepsy Behav. 2004; 5: 627–635.  [DOI](https://doi.org/10.1016/j.yebeh.2004.07.004) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/15380112/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Epilepsy%20Behav&title=What%20is%20the%20evidence%20that%20oxcarbazepine%20and%20carbamazepine%20are%20distinctly%20different%20antiepileptic%20drugs?&author=D%20Schmidt&author=CE%20Elger&volume=5&publication_year=2004&pages=627-635&pmid=15380112&doi=10.1016/j.yebeh.2004.07.004&)

11. Yang CW, Hung SI, Juo CG, et al. HLA‐B*1502‐bound peptides: implications for the pathogenesis of carbamazepine‐induced Stevens‐Johnson syndrome. J Allergy Clin Immunol. 2007; 120: 870–877.  [DOI](https://doi.org/10.1016/j.jaci.2007.06.017) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17697703/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Allergy%20Clin%20Immunol&title=HLA%E2%80%90B*1502%E2%80%90bound%20peptides:%20implications%20for%20the%20pathogenesis%20of%20carbamazepine%E2%80%90induced%20Stevens%E2%80%90Johnson%20syndrome&author=CW%20Yang&author=SI%20Hung&author=CG%20Juo&volume=120&publication_year=2007&pages=870-877&pmid=17697703&doi=10.1016/j.jaci.2007.06.017&)

12. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2007; 7: 317–323.  [DOI](https://doi.org/10.1097/ACI.0b013e3282370c5f) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17620823/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Curr%20Opin%20Allergy%20Clin%20Immunol&title=Human%20leukocyte%20antigens%20and%20drug%20hypersensitivity&author=WH%20Chung&author=SI%20Hung&author=YT%20Chen&volume=7&publication_year=2007&pages=317-323&pmid=17620823&doi=10.1097/ACI.0b013e3282370c5f&)

13. Lam NS, Yang YH, Wang LC, et al. Clinical characteristics of childhood erythema multiforme, Stevens‐Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect. 2004; 37: 366–370.  [PubMed](https://pubmed.ncbi.nlm.nih.gov/15599469/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Microbiol%20Immunol%20Infect&title=Clinical%20characteristics%20of%20childhood%20erythema%20multiforme,%20Stevens%E2%80%90Johnson%20syndrome%20and%20toxic%20epidermal%20necrolysis%20in%20Taiwanese%20children&author=NS%20Lam&author=YH%20Yang&author=LC%20Wang&volume=37&publication_year=2004&pages=366-370&pmid=15599469&)
